Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease

23 May 2025 - New treatment sparsentan has been found to slow down the progression of kidney damage, which will change ...

Read more →

FDA approves Genentech’s Susvimo for diabetic retinopathy

22 May 2025 - Genentech announced today that the US FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment ...

Read more →

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease

22 May 2025 - Approval based on the positive MATINEE and METREX Phase 3 trials. ...

Read more →

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

22 May 2025 - Dostarlimab, when used in combination with platinum-based chemotherapy, can be used as an option for the ...

Read more →

New Alzheimer’s drug available today for Australian patients

22 May 2025 - A new drug to treat the early stages of Alzheimer’s disease has been approved for use ...

Read more →

Tagrisso approved (with conditions) in Canada for patients with unresectable, stage III EGFR-mutated non-small cell lung cancer

21 May 2025 - Based on LAURA Phase 3 trial results which showed patients who took Targrisso after CRT had ...

Read more →

Lilly's Kisunla (donanemab) receives marketing authorisation in Australia for the treatment of early symptomatic Alzheimer's disease

21 May 2025 - The authorisation in Australia is for adult patients who are Apolipoprotein E-ε4 heterozygotes or non-carriers. ...

Read more →

US FDA grants approval for Jivi anti-hemophilic factor (recombinant), PEGylated-aucl in paediatric patients 7 to under 12 years of age with haemophilia A

19 May 2025 - Bayer announced that the US FDA has approved Jivi, a recombinant DNA-derived, extended half-life factor VIII ...

Read more →

US FDA approves BLA for Novavax's COVID-19 vaccine

19 May 2025 - Nuvaxovid is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the US. ...

Read more →

FDA clears first blood test used in diagnosing Alzheimer’s disease

16 May 2025 - New test provides less invasive option, reduces reliance on PET scans and increases diagnosis accessibility. ...

Read more →

MHRA approves guselkumab for Crohn’s disease and ulcerative colitis

16 May 2025 - The MHRA has today approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis. ...

Read more →

MHRA approves vaccine to protect against pneumococcal infections such as pneumonia and meningitis

15 May 2025 - The MHRA has today approved a vaccine (Capvaxive) for people aged 18 years and older to help ...

Read more →

BMS receives European Commission approval for peri-operative regimen of neo-adjuvant Opdivo (nivolumab) and chemotherapy followed by adjuvant Opdivo for resectable, high risk non-small cell lung cancer with PD-L1 expression ≥1%

16 May 2025 - Approval based on results from the CheckMate-77T trial which showed perioperative Opdivo improved event-free survival compared ...

Read more →

Amneal receives US FDA approval for Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine and cluster headaches in adults

15 May 2025 - Product will be available for appropriate patients in the second half of 2025 ...

Read more →

ICER publishes final evidence report on treatment for retinitis pigmentosa

15 May 2025 - Independent appraisal committee voted that current evidence is adequate to demonstrate a net health benefit of ...

Read more →